Biocon Ltd
Biocon Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Biosimilars segment expects significant growth with 5 new product launches in the U.S. Biocon aims for mid-teen percentage growth over the next 2-3 years, driven notably by peptides like Liraglutide (FY 2026) and Semaglutide (FY 2027), with significant contributions expected by FY 2028.
From Biocon Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Biosimilars segment expects significant growth with 5 new product launches in the U.S. and 3 globally in the next 12 months; further products planned post-2028.
- Generics business recovery driven by launch of first GLP generic (Liraglutide) in the U.K. and EU in Q4 FY25, with additional U.S. launches following; mid-teens growth expected from FY26 onwards.
- Biocon Biologics targets mid-teen percentage growth over the next 2-3 years, led by peptides like Liraglutide (FY26), Semaglutide (FY27), and others in FY28; expanded capacities will support volume increase.
- Increased sales volumes anticipated with ramp-up of API production and new manufacturing facilities (e.g., Liraglutide API, Vizag plant).
2 more points from Biocon Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Biocon Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Significant capacity expansion at Bengaluru facility and Vizag facility to increase production volumes; Vizag facility recently validated for Pimecrolimus.
- Insulin drug product manufacturing capacity has doubled and drug substance capacity in Malaysia is being expanded, expected to double in next couple of years.
- Vizag facility is being used for both captive consumption and external API customers; strategic customers in U.S. and Brazil qualifying Vizag to reduce dependence on Bengaluru.
- Cranbury (U.S.) facility acquired and expanded to manufacture products locally and participate in government contracts; additional capacity ready by mid-calendar year.
- Investment in new product launches like Stelara, oncology and insulin segments.
2 more points from Biocon Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Biocon Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Biocon Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Biocon Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Biocon Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- NGL Fine Chem (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
Arthneeti Pro · Annual
Biocon Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Biocon Ltd Q3 FY25 results?
Biosimilars segment expects significant growth with 5 new product launches in the U.S. Biocon aims for mid-teen percentage growth over the next 2-3 years, driven notably by peptides like Liraglutide (FY 2026) and Semaglutide (FY 2027), with significant contributions expected by FY 2028.
What is Biocon Ltd share price analysis?
Biocon Ltd currently shows a neutral. The stock trades at a P/E of 95.3 with a market cap of ₹69,295 Cr. Investors should review the full earnings analysis for detailed insights.
Is Biocon Ltd planning capital expenditure?
Significant capacity expansion at Bengaluru facility and Vizag facility to increase production volumes; Vizag facility recently validated for Pimecrolimus. - Insulin drug product manufacturing capacity has doubled and drug substance capacity in Malaysia is being expanded, expected to double in next couple of years. - Vizag facility is being used for both captive consumption and external API customers; strategic customers in U.S.
Keep Biocon Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.